Cytosorbents Corp. (CTSO) is a publicly traded Healthcare sector company. As of May 21, 2026, CTSO trades at $0.46 with a market cap of $30.08M and a P/E ratio of -2.41. CTSO moved +0.00% today. Year to date, CTSO is -29.44%; over the trailing twelve months it is -44.08%. Its 52-week range spans $0.45 to $1.61. Analyst consensus is neutral with an average price target of $0.75. Rallies surfaces CTSO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
CytoSorbents Q1 Revenue Up 2% to $8.9M; Cash at $6.4M, FDA Filing Planned: CytoSorbents posted Q1 revenue of $8.9M, up 2%, with a 69% gross margin, and operating loss narrowed to $3.0M, while net loss widened to $5.1M ($0.08/share). The company ended with $6.4M cash and plans to file a new DrugSorb-ATR De Novo application in late 2026 after FDA feedback.
| Metric | Value |
|---|---|
| Price | $0.46 |
| Market Cap | $30.08M |
| P/E Ratio | -2.41 |
| EPS | $-0.19 |
| Dividend Yield | 0.00% |
| 52-Week High | $1.61 |
| 52-Week Low | $0.45 |
| Volume | 1.59K |
| Avg Volume | 0 |
| Revenue (TTM) | $37.20M |
| Net Income | $-11.85M |
| Gross Margin | 71.00% |
1 analysts cover CTSO: 0 strong buy, 0 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $0.75.